← All trials
NCT04489732
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Jun 30, 2023
- Completion date
- May 31, 2024
- First posted
- Jul 28, 2020
- Last posted
- Dec 1, 2021
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of WisconsinLead sponsor
- University of WisconsinOverall official - principal investigator
- University of WisconsinStudy director
- National Institute of Dental and Craniofacial Research (NIDCR)Collaborator
- University of WisconsinCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.